Given that OCI-AML3 cells naturally carrying NPM1-mA exhibit increased TP53INP2 levels and increased sensitivity to TRAIL treatment and that NPM1 mutations are recognized as AML-initiating lesions [22], we investigated whether NPM1-mA is involved in regulating the effect of TP53INP2 on TRAIL sensitivity. The gene discussed is TP53INP2; the disease is acute myeloid leukemia.